CClinicalTrials.gg
CompletedNCT05600270Updated Oct 31, 2024Results posted

Angled-tip vs. Straight-tip Guidewire in Biliary Cannulation

An interventional study of Angled guidewire and Straight guidewire in Bile Duct Diseases, sponsored by Neev Mehta. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Neev Mehta · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigators aim is to compare outcomes between an angled-tip guidewire and a straight-tip guidewire in cannulation of the common bile duct during ERCP. This is a randomized, controlled, single-blinded study. The primary outcome is success of cannulation and secondary outcomes are incidence of post-ERCP pancreatitis, procedure duration, and rate of complication between the angled wire and straight wire.

Read the detailed description

Wire-guided cannulation of the common bile duct is a standard technique utilized during Endoscopic Retrograde Cholangio-Pancreatography (ERCP) to ensure safe and effective access to the common bile duct via the ampulla of Vater. Due to the anatomy of the ampulla, and the orientation of the biliary orifice, a guidewire with an angled tip may allow easier and safer access to the common bile duct without inadvertent manipulation of the pancreatic duct. The investigators aim to assess the technical and clinical outcomes between an angled-tip guidewire (GW) compared to a straight-tip guidewire in wire-guided cannulation of the common bile duct. The investigators hypothesize that an angled-tip GW is associated with increased rate of successful cannulation, decreased procedure time and decreased rate of post-ERCP pancreatitis in wire-guided biliary cannulation during ERCP.

02

Conditions studied

  • Bile Duct Diseases

Browse trials for

Keywords

  • ERCP
03

In context

Bile Duct Diseases

56 studies on the registry are indexed under Bile Duct Diseases; 16 are open to participants now.

This study's enrollment of 70 is below the median of 93 across 34 interventional studies indexed under Bile Duct Diseases.

Browse Bile Duct Diseases studies →

Lead sponsor

This is the only study on the registry with Neev Mehta as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • patients undergoing ERCP for cholangiography, bile or tissue sampling from the gallbladder or bile duct
  • patients undergoing ERCP for treatment of biliary diseases (removal of common bile duct stones, biliary stent placement)

Exclusion criteria

Exclusion Criteria:

  • Patients who are less than 18 years old
  • Pregnant patients
  • Patients who have undergone previous bile duct cannulation or sphincterotomy
  • Patients who have undergone prior endoscopic balloon dilation or needle-knife fistulotomy
  • Patients who have undergone gastric surgery (Billroth gastrectomy II, Roux-en-Y gastric bypass)
  • Patients with acute pancreatitis
  • Patients who refuse endoscopic intervention
  • Patients with ampullary tumor, duodenal stenosis, or pre-operatively proven pancreaticobiliary malunion
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    Angled wire

    Angled guidewire intervention arm

    Device: Angled guidewire

  • Active comparator
    Straight wire

    Straight guidewire intervention arm

    Device: Straight guidewire

Interventions

  • DeviceAngled guidewire

    Cannulation of the common bile duct using an angled-tip guidewire during ERCP

  • DeviceStraight guidewire

    Cannulation of the common bile duct using an straight-tip guidewire during ERCP

06

What researchers measure

Primary outcomes

  1. Cannulation

    Rate of successful cannulation of common bile duct

    Time frame: Day of Procedure

Secondary outcomes

  1. Post ERCP Pancreatitis

    Number of participants who develop post ERCP pancreatitis

    Time frame: Procedure day and up to day 5 post procedure

  2. Duration

    Total duration of procedure

    Time frame: Day of procedure

07

Results

Posted Oct 31, 2024

Participant flow

Participant flow — Overall Study
MilestoneAngled WireStraight Wire
Started3333
Completed3333
Not completed00

Outcome measures

PrimaryCannulation

Rate of successful cannulation of common bile duct

Time frame:
Day of Procedure
Reported as:
Count of participants · Participants
Cannulation
ParticipantsAngled WireStraight Wire
Cannulation3031
SecondaryPost ERCP Pancreatitis

Number of participants who develop post ERCP pancreatitis

Time frame:
Procedure day and up to day 5 post procedure
Reported as:
Count of participants · Participants
Post ERCP Pancreatitis
ParticipantsAngled WireStraight Wire
Post ERCP Pancreatitis12
SecondaryDuration

Total duration of procedure

Time frame:
Day of procedure
Reported as:
Mean · seconds
Duration
secondsAngled WireStraight Wire
Duration1964.26 (557 to 8520)1569.03 (711 to 4368)

Adverse events

Collected over Randomization on day of procedure to post procedure day 5. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Angled Wire0/33 (0%)1/33 (3%)0/33 (0%)
Straight Wire0/33 (0%)2/33 (6.1%)0/33 (0%)
Most frequent serious events
Most frequent serious events
EventAngled WireStraight Wire
post ERCP PancreatitisGastrointestinal disorders1/332/33
PerforationGastrointestinal disorders0/330/33
BleedingGastrointestinal disorders0/330/33
Post ERCP CholangitisInfections and infestations0/330/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Angled WireStraight WireTotal
Mean70.42 (33 to 93)60.66 (31 to 96)68.18 (31 to 96)
Sex: Female, Male
Sex: Female, Male(Participants)Angled WireStraight WireTotal
Female121729
Male211637
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Angled WireStraight WireTotal
Count of participants——0
08

Study locations

1 site
  • Lahey Hospital and Medical Center
    Burlington, Massachusetts 01805, United States
09

References and documents

Publications

  • Vihervaara H, Gronroos JM, Koivisto M, Gullichsen R, Salminen P. Angled- or straight-tipped hydrophilic guidewire in biliary cannulation: a prospective, randomized, controlled trial. Surg Endosc. 2013 Apr;27(4):1281-6. doi: 10.1007/s00464-012-2596-6. Epub 2012 Dec 19. PubMed 23250671 ↗

Study documents

  • Protocol and statistical analysis plan · Aug 29, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05600270
Lead sponsor
Neev Mehta
Responsible party
Neev Mehta (Study Coordinator, Lahey Clinic) — Sponsor-investigator
First posted
Oct 31, 2022
Start date
Oct 22, 2022
Primary completion
Aug 24, 2023
Completion
Aug 24, 2023
Results posted
Oct 31, 2024
Last update
Oct 31, 2024

Study contacts

Ann Marie Joyce, MD
principal investigator · Lahey Hospital & Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion